Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Real-time reverse transcription-pcr assay panel for middle east respiratory syndrome coronavirus
Journal of Clinical Microbiology, Volume 52, No. 1, Year 2014
Notification
URL copied to clipboard!
Description
A new human coronavirus (CoV), subsequently named Middle East respiratory syndrome (MERS)-CoV, was first reported in Saudi Arabia in September 2012. In response, we developed two real-time reverse transcription-PCR (rRT-PCR) assays targeting the MERS-CoV nucleocapsid (N) gene and evaluated these assays as a panel with a previously published assay targeting the region upstream of the MERS-CoV envelope gene (upE) for the detection and confirmation of MERS-CoV infection. All assays detected< 10 copies/reaction of quantified RNA transcripts, with a linear dynamic range of 8 log units and 1.3103 50% tissue culture infective doses (TCID50)/ml of cultured MERS-CoV per reaction. All assays performed comparably with respiratory, serum, and stool specimens spiked with cultured virus. No false-positive amplifications were obtained with other human coronaviruses or common respiratory viral pathogens or with 336 diverse clinical specimens from non-MERS-CoV cases; specimens from two confirmed MERS-CoV cases were positive with all assay signatures. In June 2012, the U.S. Food and Drug Administration authorized emergency use of the rRT-PCR assay panel as an in vitro diagnostic test for MERS-CoV. A kit consisting of the three assay signatures and a positive control was assembled and distributed to public health laboratories in the United States and internationally to support MERS-CoV surveillance and public health responses. Copyright © 2014, American Society for Microbiology.
Authors & Co-Authors
Lu, Xiaoyan
Thailand
Division of Viral Diseases
Whitaker, Brett L.
Thailand
Division of Viral Diseases
Sakthivel, Senthilkumar Kumar K.
Thailand
Division of Viral Diseases
Kamili, Shifaq
Thailand
Division of Viral Diseases
Rose, Laura J.
Thailand
Division of Preparedness and Emerging Infections
Lowe, Luis E.
Thailand
Division of Preparedness and Emerging Infections
Mohareb, Emad W.
United States, Atlanta
Centers for Disease Control and Prevention
Elassal, Emad Maher Labib
United States, Atlanta
Centers for Disease Control and Prevention
Al-Sanouri, Tarek M.
Jordan, Amman
Ministry of Health
Haddadin, Aktham Jeries
Jordan, Amman
Ministry of Health
Erdman, Dean D.
Thailand
Division of Viral Diseases
Statistics
Citations: 151
Authors: 11
Affiliations: 4
Identifiers
Doi:
10.1128/JCM.02533-13
ISSN:
00951137
e-ISSN:
1098660X
Research Areas
Covid
Food Security
Genetics And Genomics